Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Statistics
Share Statistics
Summit Therapeutics has 737.63M shares outstanding. The number of shares has increased by 5.08% in one year.
| Shares Outstanding | 737.63M |
| Shares Change (YoY) | 5.08% |
| Shares Change (QoQ) | 0.07% |
| Owned by Institutions (%) | 12.74% |
| Shares Floating | 111.13M |
| Failed to Deliver (FTD) Shares | 12.75K |
| FTD / Avg. Volume | 0.45% |
Short Selling Information
The latest short interest is 21.63M, so 2.93% of the outstanding shares have been sold short.
| Short Interest | 21.63M |
| Short % of Shares Out | 2.93% |
| Short % of Float | 19.47% |
| Short Ratio (days to cover) | 6.98 |
Valuation Ratios
The PE ratio is -57.95 and the forward PE ratio is -50.12. Summit Therapeutics's PEG ratio is 0.84.
| PE Ratio | -57.95 |
| Forward PE | -50.12 |
| PS Ratio | 0 |
| Forward PS | 9.5 |
| PB Ratio | 32.99 |
| P/FCF Ratio | -90.17 |
| PEG Ratio | 0.84 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Summit Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.15, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.15 |
| Quick Ratio | 10.15 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 23.06 |
| Debt / FCF | -0.05 |
| Interest Coverage | -0.04 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.39M |
| Employee Count | 159 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 593.79% in the last 52 weeks. The beta is -0.46, so Summit Therapeutics's price volatility has been lower than the market average.
| Beta | -0.46 |
| 52-Week Price Change | 593.79% |
| 50-Day Moving Average | 20 |
| 200-Day Moving Average | 17.85 |
| Relative Strength Index (RSI) | 63.27 |
| Average Volume (20 Days) | 2.84M |
Income Statement
| Revenue | n/a |
| Gross Profit | -15.01M |
| Operating Income | 313K |
| Net Income | -221.31M |
| EBITDA | 313K |
| EBIT | -230M |
| Earnings Per Share (EPS) | -0.31 |
Balance Sheet
The company has 104.86M in cash and 7.22M in debt, giving a net cash position of 97.64M.
| Cash & Cash Equivalents | 104.86M |
| Total Debt | 7.22M |
| Net Cash | 97.64M |
| Retained Earnings | -1.21B |
| Total Assets | 435.56M |
| Working Capital | 382.02M |
Cash Flow
In the last 12 months, operating cash flow was -142.11M and capital expenditures -139K, giving a free cash flow of -142.25M.
| Operating Cash Flow | -142.11M |
| Capital Expenditures | -139K |
| Free Cash Flow | -142.25M |
| FCF Per Share | -0.2 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SMMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SMMT is $33.5, which is 36.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $33.5 |
| Price Target Difference | 36.4% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | 215.26 |
| Piotroski F-Score | 4 |